Lenvatinib
- PDF / 150,913 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 75 Downloads / 177 Views
1 S
Lenvatinib Destructive thyroiditis: case report
An 80-year-old woman developed destructive thyroiditis during treatment with lenvatinib for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). The woman, who had HCC with PVTT, started receiving lenvatinib 8mg daily. One week later, she developed grade 1 stomatitis and hand-to-foot syndrome. Even after that, treatment with oral lenvatinib was continued. Her lab tests showed increased serum free T3 (FT 3) and free T4 (FT4) and decreased thyroid stimulating horizon (TSH). Thyroid poisoning due to lenvatinib was suspected. The dose of lenvatinib was reduced to 4mg and the woman was treated with thiamazole. Subsequently, her serum FT3, FT4 and TSH were normalised. At 21 weeks of lenvatinib treatment, her lab tests again showed decrease in thyroid function. He was treated with levothyroxine sodium and her thyroid function restored. After 43 weeks, CT scan confirmed no nodal shadow in the lungs and necrosis of the liver tumour. Lenvatinib was continued at 4mg every other day. Kobayashi K, et al. A patient with advanced hepatocellular carcinoma and portal vein tumor thrombosis who showed a complete response to lenbatinib despite the complication of destructive thyroiditis. Kanzo 61: 410-417, No. 8, 2020. Available from: URL: http://doi.org/10.2957/kanzo.61.410 [Japanese; summarised from a translation]
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803501215
Reactions 19 Sep 2020 No. 1822
Data Loading...
